18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications

BackgroundTo compare the performance of fluorine-18-fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) and conventional tests for cancer screening in autoimmune inflammatory myopathy (AIM) patients.Patients and methodsWe carried out a retrospective cohort study of AIM patients from one academ